Paracetamol, naproxen, caffeine (Pentalgin Neo) – [20 tablets]

Naproxen: non-steroidal anti-inflammatory drug, has analgesic, antipyretic and anti-inflammatory effects. Mechanism of action is due to non-selective inhibition of cyclooxygenase-1 and -2 (COX-1, COX-2) activity, which regulates the synthesis of prostaglandins. The use of naproxen in the form of sodium naproxen salt provides faster absorption and rapid onset of analgesic effect.

Paracetamol: non-narcotic analgesic, has antipyretic and analgesic effect, due to blockade of cyclooxygenase in the central nervous system and effects on the centers of pain and thermoregulation.

Caffeine: reduces sleepiness and fatigue, increases mental and physical performance, dilates blood vessels of skeletal muscles, heart, kidneys, reduces platelet aggregation. In this combination, caffeine at a low dose has almost no simulative effect on the central nervous system, increases the tone of cerebral vessels and helps accelerate blood flow. Caffeine increases the permeability of histohematic barriers and increases the bioavailability of non-narcotic analgesics, and also reduces the activity of COX, as it is an antagonist of adenosine A(2A) and A(2B) receptors, which contributes to enhance the analgesic effect.

In a registration clinical trial of Pentalgin® NEO, superiority in the effect on overall pain relief (TOTPAR score) over naproxen monodrug and over the combined preparation of paracetamol and caffeine was confirmed.

Pain syndrome of different genesis:

– In diseases of the musculoskeletal system (osteoarthritis of the peripheral joints and spine, including radicular syndrome, arthritis, myalgia);

– neuralgia;

– toothache;

– headache, migraine;

– algodysmenorrhea;

– Post-traumatic (sprains and bruises) and postoperative pain syndrome accompanied by inflammation.

The drug Pentalgin® NEO is used for symptomatic therapy (for pain and inflammation reduction) and has no effect on the progression of the underlying disease.

– Hypersensitivity to naproxen, naproxen sodium, other nonsteroidal anti-inflammatory drugs (NSAIDs), or xanthines; hypersensitivity to other components of the drug;

– complete or incomplete combination of bronchial asthma, recurrent nasal or paranasal sinus polyposis and intolerance to acetylsalicylic acid and other NSAIDs (including history);

– period after aortocoronary bypass surgery;

– gastrointestinal erosive and ulcerative lesions (acute phase), active gastrointestinal bleeding;

– hemophilia and other disorders of blood clotting and hemostasis;

– cerebrovascular bleeding or other bleeding disorders;

– decompensated heart failure;

– organic diseases of the cardiovascular system (acute myocardial infarction, severe coronary heart disease, severe arterial hypertension), paroxysmal tachycardia, frequent ventricular extrasystoles;

– severe hepatic insufficiency or active liver disease;

– Severe renal insufficiency (creatinine clearance (CK) less than 30 ml/min), advanced renal disease, confirmed hyperkalemia;

– hyperexcitability, sleep disorders, anxiety disorders (agoraphobia, panic disorder);

– Pregnancy, breast-feeding;

– Children under 18 years of age.